Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
REDWOOD CITY, Calif., May 01, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.
- A fireside chat is scheduled at Deutche Bank’s 42nd Annual Health Care Conference on Wednesday, May 3rd at 10:40 a.m. EDT taking place in Boston, MA.
- A company presentation is scheduled at the Bank of America/Merrill Lynch Healthcare Conference on Thursday, May 18th at 8:40 a.m. PDT taking place in Las Vegas, NV.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O'Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
